Aarey Drugs (AAREYDRUGS) | Stock Overview & Key Data
Aarey Drugs Performance Comparison
Stock Range
Today's Range
Low: ₹80.57
High: ₹83.85
on October 6, 2025
52 Week Range
Low: ₹32.85
High: ₹83.90
on March 28, 2025
on October 1, 2025
All-Time High: ₹83.90 on October 1, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR2.3B
EPS
1.46
P/E Ratio (TTM)
56.32
Forward P/E
N/A
P/B Ratio
1.67
PEG Ratio
6.19
Div. Yield
N/A
ROE
2.91%
Beta
0.522
Debt to Equity
25.17
Financial Highlights
Profitability
Gross Margin
4.28%
Operating Margin
1.19%
Profit Margin
0.93%
Returns and Earnings
Return on Assets (TTM)
1.39%
Return on Equity (TTM)
2.91%
EBITDA
INR124.3M
Net Income (TTM)
INR41.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR157.88
Quarterly Revenue Growth (YoY)
-19.50%
Quarterly Earnings Growth (YoY)
10.70%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Aarey Drugs AAREYDRUGS | 2.34B Small-cap | 4.70% | 18.10% | 15.80% | 84.39% | 42.94% | 24.09% | 113.56% | 89.67% |
| Sun Pharmaceutical SUNPHARMA | 4.01T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Innova Captab INNOVACAP | 48.64B Small-cap | 0.59% | -7.07% | -0.71% | -5.56% | -23.39% | 15.25% | 57.00% | 57.00% |
| Suven Life Sciences SUVEN | 47.99B Small-cap | -0.20% | -3.13% | -15.86% | 58.76% | 63.09% | 46.77% | 186.97% | 307.88% |
| Gujarat Themis GUJTHEM | 46.19B Small-cap | 5.76% | 7.50% | 23.75% | 49.86% | 73.70% | 93.18% | 93.18% | 93.18% |
Ownership & Short Interest
Insider Ownership
50.58%
Institutional Ownership
1.73%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
81K
Average 90-Day Volume
55K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AAREYDRUGS's 52-week high and low?
- In the last 52 weeks, Aarey Drugs reached a high of ₹83.90 (on October 1, 2025) and a low of ₹32.85 (on March 28, 2025).
- What is the market cap and P/E ratio for AAREYDRUGS?
- Curious about Aarey Drugs's size and valuation? Its market capitalization stands at 2.34B. When it comes to valuation, the P/E ratio (trailing twelve months) is 56.32, and the forward P/E (looking ahead) is N/A.
- Does AAREYDRUGS pay dividends? If so, what's the yield?
- As for dividends, Aarey Drugs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Aarey Drugs's main competitors or similar companies to consider before investing?
When looking at Aarey Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA4.01T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Innova Captab
INNOVACAP48.64B Healthcare Drug Manufacturers - Specialty & Generic 15.25% 57.00% Suven Life Sciences
SUVEN47.99B Healthcare Drug Manufacturers - Specialty & Generic 46.77% 186.97% Gujarat Themis
GUJTHEM46.19B Healthcare Drug Manufacturers - Specialty & Generic 93.18% 93.18% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aarey Drugs & Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Aarey Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 2.91%, the Debt to Equity ratio from the most recent quarter is 25.17, and its Gross Profit Margin stands at 4.28%.
- What is the recent revenue and earnings growth for AAREYDRUGS?
- Looking at Aarey Drugs's growth, its revenue over the trailing twelve months (TTM) was INR4B. Compared to the same quarter last year (YoY), quarterly revenue grew by -19.50%, and quarterly earnings saw a YoY growth of 10.70%.
- How much of AAREYDRUGS stock is held by insiders and institutions?
- Wondering who owns Aarey Drugs stock? Company insiders (like executives and directors) hold about 50.58% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 1.73%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.